Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs

Core Viewpoint - Amgen Inc. has acquired Dark Blue Therapeutics for up to $840 million, focusing on precision oncology medicines, particularly for leukemia treatments [1][2]. Group 1: Acquisition Details - The acquisition values Dark Blue Therapeutics at up to $840 million, which includes both upfront payments and future milestones [1]. - Dark Blue's lead candidate, DBT 3757, is in IND-enabling studies for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) [2]. Group 2: Strategic Importance - Amgen plans to integrate Dark Blue Therapeutics into its existing research organization, enhancing its early oncology discovery efforts [3]. - The acquisition complements Amgen's research in targeted protein degradation and leukemia therapeutics, aligning with its strategy to invest in novel therapeutic targets [4]. Group 3: Market Reaction - Following the acquisition announcement, Amgen's shares rose by 2.89% to $339.71, nearing its 52-week high of $346.38 [5].